{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:23:11Z","timestamp":1792174991085,"version":"4.4.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s40618-021-01729-8","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:04:16Z","timestamp":1643328256000},"page":"989-998","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Transcriptome-guided resolution of tumor microenvironment interactions in pheochromocytoma and paraganglioma subtypes"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1531-9682","authenticated-orcid":false,"given":"S.","family":"Batchu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hakim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. S.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Madzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Atabek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. R.","family":"Spitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. K.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,28]]},"reference":[{"key":"1729_CR1","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.3747\/co.21.1579","volume":"21","author":"M Lefebvre","year":"2014","unstructured":"Lefebvre M, Foulkes WD (2014) Pheochromocytoma and paraganglioma syndromes: genetics and management update. Curr Oncol 21:e8\u2013e17","journal-title":"Curr Oncol"},{"key":"1729_CR2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/ncpendmet0396","volume":"3","author":"K Pacak","year":"2007","unstructured":"Pacak K, Eisenhofer G, Ahlman H et al (2007) Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nat Clin Pract Endocrinol Metab 3:92\u2013102","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"1729_CR3","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1210\/jc.2014-1498","volume":"99","author":"JW Lenders","year":"2014","unstructured":"Lenders JW, Duh QY, Eisenhofer G et al (2014) Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:1915\u20131942. https:\/\/doi.org\/10.1210\/jc.2014-1498","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1729_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","volume":"31","author":"L Fishbein","year":"2017","unstructured":"Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR et al (2017) Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell 31(2):181\u2013193","journal-title":"Cancer Cell"},{"key":"1729_CR5","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.molcel.2009.09.006","volume":"35","author":"X Huang","year":"2009","unstructured":"Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, Ang KK, Story M, Le QT, Giacci AJ (2009) Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell 35:856\u2013867","journal-title":"Mol Cell"},{"issue":"11","key":"1729_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11864-020-00787-z","volume":"21","author":"M Ilanchezhian","year":"2020","unstructured":"Ilanchezhian M, Jha A, Pacak K, Del Rivero J (2020) Emerging treatments for advanced\/metastatic pheochromocytoma and paraganglioma. Curr Treat Options Oncol 21(11):85. https:\/\/doi.org\/10.1007\/s11864-020-00787-z (PMID:32862332;PMCID:PMC7456409)","journal-title":"Curr Treat Options Oncol"},{"key":"1729_CR7","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41392-020-00280-x","volume":"5","author":"MZ Jin","year":"2020","unstructured":"Jin MZ, Jin WL (2020) The updated landscape of tumor microenvironment and drug repurposing. Sig Transduct Target Ther 5:166. https:\/\/doi.org\/10.1038\/s41392-020-00280-x","journal-title":"Sig Transduct Target Ther"},{"key":"1729_CR8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/PAP.0000000000000162","volume":"24","author":"S Hendry","year":"2017","unstructured":"Hendry S, Salgado R, Gevaert T et al (2017) Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology biomarkers working group: part 1: assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research. Adv Anat Pathol 24:235\u2013251","journal-title":"Adv Anat Pathol"},{"key":"1729_CR9","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1097\/JTO.0b013e3182037b76","volume":"6","author":"RM Bremnes","year":"2011","unstructured":"Bremnes RM, Al-Shibli K, Donnem T et al (2011) The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J Thorac Oncol 6:824\u2013833","journal-title":"J Thorac Oncol"},{"key":"1729_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01443-x","author":"S Batchu","year":"2020","unstructured":"Batchu S (2020) Age-related differences of immune infiltrates in pheochromocytomas and paragangliomas. J Endocrinol Invest. https:\/\/doi.org\/10.1007\/s40618-020-01443-x","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"1729_CR11","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2019","unstructured":"Thorsson V, Gibbs DL, Brown SD et al (2019) The immune landscape of cancer [published correction appears in immunity. 51(2):411-412]. Immunity 48(4):812\u2013830","journal-title":"Immunity"},{"issue":"15","key":"1729_CR12","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1158\/1078-0432.CCR-17-3509","volume":"24","author":"D Tamborero","year":"2018","unstructured":"Tamborero D, Rubio-Perez C, Mui\u00f1os F et al (2018) A pan-cancer landscape of interactions between solid tumors and infiltrating immune cell populations. Clin Cancer Res 24(15):3717\u20133728","journal-title":"Clin Cancer Res"},{"key":"1729_CR13","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41592-020-0858-0","volume":"17","author":"JJL Goh","year":"2020","unstructured":"Goh JJL, Chou N, Seow WY et al (2020) Highly specific multiplexed RNA imaging in tissues with split-FISH. Nat Methods 17:689\u2013693. https:\/\/doi.org\/10.1038\/s41592-020-0858-0","journal-title":"Nat Methods"},{"key":"1729_CR14","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/s41592-019-0548-y","volume":"16","author":"S Vickovic","year":"2019","unstructured":"Vickovic S, Eraslan G, Salm\u00e9n F et al (2019) High-definition spatial transcriptomics for in situ tissue profiling. Nat Methods 16:987\u2013990. https:\/\/doi.org\/10.1038\/s41592-019-0548-y","journal-title":"Nat Methods"},{"key":"1729_CR15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nature20123","volume":"539","author":"I Tirosh","year":"2016","unstructured":"Tirosh I et al (2016) Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. Nature 539:309\u2013313","journal-title":"Nature"},{"key":"1729_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13073-020-00741-6","volume":"12","author":"HW Lee","year":"2020","unstructured":"Lee HW et al (2020) Single-cell RNA sequencing reveals the TME and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient. Genome Med 12:47","journal-title":"Genome Med"},{"key":"1729_CR17","doi-asserted-by":"publisher","first-page":"6322","DOI":"10.1038\/s41467-020-20059-6","volume":"11","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Yang D, Yang Q et al (2020) Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma. Nat Commun 11:6322. https:\/\/doi.org\/10.1038\/s41467-020-20059-6","journal-title":"Nat Commun"},{"key":"1729_CR18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-2352","author":"U Ghoshdastider","year":"2021","unstructured":"Ghoshdastider U, Rohatgi N, Mojtabavi Naeini M, Baruah P, Revkov E, Guo YA, Rizzetto S, Wong AML, Solai S, Nguyen TT, Yeong JPS, Iqbal J, Tan PH, Chowbay B, Dasgupta R, Skanderup AJ (2021) Pan-cancer analysis of ligand-receptor crosstalk in the tumor microenvironment. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-2352 (Epub ahead of print. PMID: 33547160)","journal-title":"Cancer Res"},{"key":"1729_CR19","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Mart\u00ednez E, Vegesna R, Kim H, Torres-Garcia W et al (2013) Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 4:2612","journal-title":"Nat Commun"},{"issue":"21","key":"1729_CR20","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1093\/bioinformatics\/btv370","volume":"31","author":"N Zhang","year":"2015","unstructured":"Zhang N, Wu HJ, Zhang W, Wang J, Wu H, Zheng X (2015) Predicting tumor purity from methylation microarray data. Bioinformatics 31(21):3401\u20133405. https:\/\/doi.org\/10.1093\/bioinformatics\/btv370 (Epub 2015 Jun 25 PMID: 26112293)","journal-title":"Bioinformatics"},{"key":"1729_CR21","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson MD, Hayes DN (2010) ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 26:1572\u20131573","journal-title":"Bioinformatics"},{"key":"1729_CR22","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1198\/016214508000000454","volume":"103","author":"Y Liu","year":"2008","unstructured":"Liu Y, Hayes DN, Nobel A, Marron JS (2008) Statistical significance of clustering for high-dimension, low-sample size data. J Am Stat Assoc 103:1281\u20131293","journal-title":"J Am Stat Assoc"},{"key":"1729_CR23","doi-asserted-by":"publisher","first-page":"7866","DOI":"10.1038\/ncomms8866","volume":"6","author":"JA Ramilowski","year":"2015","unstructured":"Ramilowski JA, Goldberg T, Harshbarger J, Kloppman E, Lizio M, Satagopam VP, Itoh M, Kawaji H, Carninci P, Rost B et al (2015) A draft network of ligand\u2013receptor mediated multicellular signalling in human. Nat Commun 6:7866","journal-title":"Nat Commun"},{"key":"1729_CR24","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/656340","volume":"2012","author":"EN Rozali","year":"2012","unstructured":"Rozali EN, Hato SV, Robinson BW, Lake RA, Lesterhuis WJ (2012) Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol 2012:656340. https:\/\/doi.org\/10.1155\/2012\/656340","journal-title":"Clin Dev Immunol"},{"key":"1729_CR25","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1158\/1078-0432.CCR-16-1761","volume":"23","author":"JH Yearley","year":"2017","unstructured":"Yearley JH, Gibson C, Yu N, Moon C, Murphy E, Juco J, Lunceford J, Cheng J, Chow LQM, Seiwert TY et al (2017) PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Clin Cancer Res 23:3158\u20133167. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1761","journal-title":"Clin Cancer Res"},{"issue":"24","key":"1729_CR26","doi-asserted-by":"publisher","first-page":"8426","DOI":"10.1158\/1078-0432.CCR-04-0821","volume":"10","author":"M K\u00f6rner","year":"2004","unstructured":"K\u00f6rner M, Waser B, Reubi JC (2004) High expression of neuropeptide y receptors in tumors of the human adrenal gland and extra-adrenal paraganglia. Clin Cancer Res 10(24):8426\u20138433. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0821 (PMID: 15623622)","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1729_CR27","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1164\/rccm.201703-0660OC","volume":"197","author":"D Ajona","year":"2018","unstructured":"Ajona D, Zandueta C, Corrales L, Moreno H, Pajares MJ, Ortiz-Espinosa S, Mart\u00ednez-Terroba E, Perurena N, de Miguel FJ, Jantus-Lewintre E, Camps C, Vicent S, Agorreta J, Montuenga LM, Pio R, Lecanda F (2018) Blockade of the complement C5a\/C5aR1 axis impairs lung cancer bone metastasis by CXCL16-mediated effects. Am J Respir Crit Care Med 197(9):1164\u20131176. https:\/\/doi.org\/10.1164\/rccm.201703-0660OC (PMID:29327939;PMCID:PMC6835094)","journal-title":"Am J Respir Crit Care Med"},{"key":"1729_CR28","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1158\/0008-5472.448.65.2","volume":"65","author":"T Rothhammer","year":"2005","unstructured":"Rothhammer T, Poser I, Soncin F, Bataille F, Moser M, Bosserhoff AK (2005) Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res 65:448\u2013456","journal-title":"Cancer Res"},{"key":"1729_CR29","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/gcc.20307","volume":"45","author":"EL Alarmo","year":"2006","unstructured":"Alarmo EL, Rauta J, Kauraniemi P, Karhu R, Kuukasj\u00e4rvi T, Kallioniemi A (2006) Bone morphogenetic protein 7 is widely overexpressed in primary breast cancer. Genes Chromosom Cancer 45:411\u2013419","journal-title":"Genes Chromosom Cancer"},{"key":"1729_CR30","first-page":"389","volume":"46","author":"D Bobinac","year":"2005","unstructured":"Bobinac D, Mari\u0107 I, Zorici\u0107 S, Spanjol J, Dordevi\u0107 G, Musta\u0107 E, Fuckar Z (2005) Expression of bone morphogenetic proteins in human metastatic prostate and breast cancer. Croat Med J 46:389\u2013396","journal-title":"Croat Med J"},{"key":"1729_CR31","first-page":"327","volume":"7","author":"SR Davies","year":"2008","unstructured":"Davies SR, Watkins G, Douglas-Jones A, Mansel RE, Jiang WG (2008) Bone morphogenetic proteins 1 to 7 in human breast cancer, expression pattern and clinical\/prognostic relevance. J Exp Ther Oncol 7:327\u2013338","journal-title":"J Exp Ther Oncol"},{"key":"1729_CR32","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.3892\/ijmm.2011.872","volume":"29","author":"Y Liu","year":"2012","unstructured":"Liu Y, Chen J, Yang Y, Zhang L, Jiang WG (2012) \u039colecular impact of bone morphogenetic protein 7, on lung cancer cells and its clinical significance. Int J Mol Med 29:1016\u20131024","journal-title":"Int J Mol Med"},{"issue":"9","key":"1729_CR33","doi-asserted-by":"publisher","first-page":"16052","DOI":"10.18632\/oncotarget.14109","volume":"8","author":"YK Chae","year":"2017","unstructured":"Chae YK, Ranganath K, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, Matsangou M, Costa R, Carneiro B, Villaflor VM, Cristofanilli M, Giles FJ (2017) Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget 8(9):16052\u201316074. https:\/\/doi.org\/10.18632\/oncotarget.14109 (PMID:28030802;PMCID:PMC5362545)","journal-title":"Oncotarget"},{"key":"1729_CR34","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1042\/BJ20101603","volume":"437","author":"J Wesche","year":"2011","unstructured":"Wesche J, Haglund K, Haugsten EM (2011) Fibroblast growth factors and their receptors in cancer. Biochem J 437:199\u2013213. https:\/\/doi.org\/10.1042\/BJ20101603","journal-title":"Biochem J"},{"key":"1729_CR35","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nrc.2017.8","volume":"17","author":"IS Babina","year":"2017","unstructured":"Babina IS, Turner NC (2017) Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer 17:318\u2013332. https:\/\/doi.org\/10.1038\/nrc.2017.8","journal-title":"Nat Rev Cancer"},{"issue":"487","key":"1729_CR36","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.mce.2019.02.001","volume":"1","author":"T Thanasupawat","year":"2019","unstructured":"Thanasupawat T, Glogowska A, Nivedita-Krishnan S, Wilson B, Klonisch T, Hombach-Klonisch S (2019) Emerging roles for the relaxin\/RXFP1 system in cancer therapy. Mol Cell Endocrinol 1(487):85\u201393. https:\/\/doi.org\/10.1016\/j.mce.2019.02.001 (Epub 2019 Feb 11 PMID: 30763603)","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"1729_CR37","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1158\/1078-0432.CCR-18-2312","volume":"25","author":"M Spino","year":"2019","unstructured":"Spino M, Kurz SC, Chiriboga L, Serrano J, Zeck B, Sen N, Patel S, Shen G, Vasudevaraja V, Tsirigos A, Suryadevara CM, Frenster JD, Tateishi K, Wakimoto H, Jain R, Riina HA, Nicolaides TP, Sulman EP, Cahill DP, Golfinos JG, Isse K, Saunders LR, Zagzag D, Placantonakis DG, Snuderl M, Chi AS (2019) Cell surface notch ligand DLL3 is a therapeutic target in isocitrate dehydrogenase-mutant glioma. Clin Cancer Res 25(4):1261\u20131271. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2312 (Epub 2018 Nov 5. PMID: 30397180; PMCID: PMC7365589)","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1729_CR38","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1111\/cas.13997","volume":"110","author":"M Furuta","year":"2019","unstructured":"Furuta M, Kikuchi H, Shoji T, Takashima Y, Kikuchi E, Kikuchi J, Kinoshita I, Dosaka-Akita H, Sakakibara-Konishi J (2019) DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail. Cancer Sci 110(5):1599\u20131608. https:\/\/doi.org\/10.1111\/cas.13997 (Epub 2019 Apr 13. PMID: 30874360; PMCID: PMC6501010)","journal-title":"Cancer Sci"},{"key":"1729_CR39","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1083\/jcb.200503113","volume":"170","author":"E Ladi","year":"2005","unstructured":"Ladi E, Nichols JT, Ge W et al (2005) The divergent DSL ligand Dll3 does not activate Notch signaling but cell autonomously attenuates signaling induced by other DSL ligands. J Cell Biol 170:983\u2013992","journal-title":"J Cell Biol"},{"issue":"5","key":"1729_CR40","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/hmg\/ddq529","volume":"20","author":"G Chapman","year":"2011","unstructured":"Chapman G, Sparrow DB, Kremmer E, Dunwoodie SL (2011) Notch inhibition by the ligand DELTA-LIKE 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis. Hum Mol Genet 20(5):905\u2013916. https:\/\/doi.org\/10.1093\/hmg\/ddq529","journal-title":"Hum Mol Genet"},{"key":"1729_CR41","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.ydbio.2009.01.007","volume":"328","author":"RM Henke","year":"2009","unstructured":"Henke RM, Meredith DM, Borromeo MD, Savage TK, Johnson JE (2009) Ascl1 and Neurog2 form novel complexes and regulate Delta-like3 (Dll3) expression in the neural tube. Dev Biol 328:529\u2013540","journal-title":"Dev Biol"},{"key":"1729_CR42","doi-asserted-by":"publisher","first-page":"10680","DOI":"10.1158\/0008-5472.CAN-05-1404","volume":"65","author":"H Osada","year":"2005","unstructured":"Osada H, Tatematsu Y, Yatabe Y, Horio Y, Takahashi T (2005) ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. Cancer Res 65:10680\u201310685","journal-title":"Cancer Res"},{"key":"1729_CR43","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMra0803109","volume":"359","author":"S Frohling","year":"2008","unstructured":"Frohling S, Dohner H (2008) Chromosomal abnormalities in cancer. N Engl J Med 359:722\u2013734","journal-title":"N Engl J Med"},{"key":"1729_CR44","doi-asserted-by":"publisher","first-page":"6503","DOI":"10.1038\/sj.onc.1204816","volume":"20","author":"M Dohn","year":"2001","unstructured":"Dohn M, Jiang JY, Chen XB (2001) Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis. Oncogene 20:6503\u20136515","journal-title":"Oncogene"},{"key":"1729_CR45","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/sj.onc.1209108","volume":"25","author":"G Xia","year":"2006","unstructured":"Xia G et al (2006) EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival. Oncogene 25:769\u2013780","journal-title":"Oncogene"},{"key":"1729_CR46","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/ijc.23890","volume":"124","author":"M Guan","year":"2009","unstructured":"Guan M, Xu C, Zhang F, Ye C (2009) Aberrant methylation of EphA7 in human prostate cancer and its relation to clinicopathologic features. Int J Cancer 124:88\u201394","journal-title":"Int J Cancer"},{"key":"1729_CR47","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/j.humpath.2007.01.030","volume":"38","author":"J Wang","year":"2007","unstructured":"Wang J et al (2007) Differential expression of EphA7 receptor tyrosine kinase in gastric carcinoma. Hum Pathol 38:1649\u20131656","journal-title":"Hum Pathol"},{"key":"1729_CR48","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1182\/blood.V94.7.2477.419k13_2477_2486","volume":"94","author":"M Dottori","year":"1999","unstructured":"Dottori M, Down M, Huttmann A, Fitzpatrick DR, Boyd AW (1999) Cloning and characterization of EphA3 (Hek) gene promoter: DNA methylation regulates expression in hematopoietic tumor cells. Blood 94:2477\u20132486","journal-title":"Blood"},{"issue":"3","key":"1729_CR49","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/nrc2806","volume":"10","author":"EB Pasquale","year":"2010","unstructured":"Pasquale EB (2010) Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 10(3):165\u2013180. https:\/\/doi.org\/10.1038\/nrc2806 (PMID:20179713;PMCID:PMC2921274)","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"1729_CR50","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1210\/jc.2009-0309","volume":"94","author":"EW Lai","year":"2009","unstructured":"Lai EW, Joshi BH, Martiniova L, Dogra R, Fujisawa T, Leland P, de Krijger RR, Lubensky IA, Elkahloun AG, Morris JC, Puri RK, Pacak K (2009) Overexpression of interleukin-13 receptor-a2 in neuroendocrine malignant pheochromocytoma: a novel target for receptor directed ant-cancer therapy. J Clin Endocrinol Metab 94(8):2952\u20132957. https:\/\/doi.org\/10.1210\/jc.2009-0309 (Epub 2009 Jun 2. PMID: 19491224; PMCID: PMC2730867)","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1729_CR51","doi-asserted-by":"publisher","first-page":"5332","DOI":"10.1210\/en.2005-0474","volume":"146","author":"Y Kano","year":"2005","unstructured":"Kano Y, Otsuka F, Takeda M, Suzuki J, Inagaki K, Miyoshi T, Miyamoto M, Otani H, Ogura T, Makino H (2005) Regulatory roles of bone morphogenetic proteins and glucocorticoids in catecholamine production by rat pheochromocytoma cells. Endocrinology 146(12):5332\u20135340. https:\/\/doi.org\/10.1210\/en.2005-0474 (Epub 2005 Sep 8 PMID: 16150914)","journal-title":"Endocrinology"},{"issue":"11","key":"1729_CR52","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","volume":"19","author":"CU Blank","year":"2019","unstructured":"Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, Lynn RC, Philip M, Rao A, Restifo NP, Schietinger A, Schumacher TN, Schwartzberg PL, Sharpe AH, Speiser DE, Wherry EJ, Youngblood BA, Zehn D (2019) Defining \u201cT cell exhaustion.\u201d Nat Rev Immunol 19(11):665\u2013674. https:\/\/doi.org\/10.1038\/s41577-019-0221-9 (Epub 2019 Sep 30. PMID: 31570879; PMCID: PMC7286441)","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"1729_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.162","volume":"6","author":"Y Jiang","year":"2015","unstructured":"Jiang Y, Li Y, Zhu B (2015) T-cell exhaustion in the tumor microenvironment. Cell Death Dis 6(6):e1792. https:\/\/doi.org\/10.1038\/cddis.2015.162 (PMID:26086965;PMCID:PMC4669840)","journal-title":"Cell Death Dis"},{"issue":"11","key":"1729_CR54","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1358332","volume":"6","author":"DJ Pinato","year":"2017","unstructured":"Pinato DJ, Black JR, Trousil S, Dina RE, Trivedi P, Mauri FA, Sharma R (2017) Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior. Oncoimmunology 6(11):e1358332. https:\/\/doi.org\/10.1080\/2162402X.2017.1358332 (PMID:29147618;PMCID:PMC5674959)","journal-title":"Oncoimmunology"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01729-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-021-01729-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01729-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:34:54Z","timestamp":1674606894000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-021-01729-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,28]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1729"],"URL":"https:\/\/doi.org\/10.1007\/s40618-021-01729-8","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,28]]},"assertion":[{"value":"14 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable. This article does not contain any experiments with human participants performed by the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"For this type of study, no informed consent is required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}